Jump to main content
Jump to site search

Issue 9, 2019
Previous Article Next Article

Prodrug strategies for targeted therapy triggered by reactive oxygen species

Author affiliations

Abstract

Increased levels of reactive oxygen species (ROS) have been associated with numerous pathophysiological conditions including cancer and inflammation and the ROS stimulus constitutes a potential trigger for drug delivery strategies. Over the past decade, a number of ROS-sensitive functionalities have been identified with the purpose of introducing disease-targeting properties into small molecule drugs – a prodrug strategy that offers a promising approach for increasing the selectivity and efficacy of treatments. This review will provide an overview of the ROS-responsive prodrugs developed to date. A discussion on the current progress and limitations is provided along with a reflection on the unanswered questions that need to be addressed in order to advance this novel approach to the clinic.

Graphical abstract: Prodrug strategies for targeted therapy triggered by reactive oxygen species

Back to tab navigation

Article information


Submitted
20 Mar 2019
Accepted
03 May 2019
First published
08 May 2019

Med. Chem. Commun., 2019,10, 1531-1549
Article type
Review Article

Prodrug strategies for targeted therapy triggered by reactive oxygen species

J. Peiró Cadahía, V. Previtali, N. S. Troelsen and M. H. Clausen, Med. Chem. Commun., 2019, 10, 1531
DOI: 10.1039/C9MD00169G

Search articles by author

Spotlight

Advertisements